#biosolutions
Cooperation between government institutions and industry will lead to more green bio solutions within the Danish food industry.
Read more here⬇️ it's in English.
www.danskindustri.dk/om-di/kontak...
DI: Nye anbefalinger skal styrke danske fødevarer og biosolutions - DI
Vækstteamet for fremtidens landbrug, fødevarer og biosolutions er i dag kommet med anbefalinger til, hvordan Danmark kan omsætte grønne ambitioner til konkurrenceevne og vækst. DI opfordrer regeringen til at følge anbefalingerne op med en ny fødevarestrategi og en målrettet indsats for danske biosolutions.
www.danskindustri.dk
November 19, 2026 at 7:29 AM
Boston’s Asimov and Emergent BioSolutions are developing research cell banks for two Ebola antibody candidates, an early step toward making material for study.
Boston’s Asimov Takes an Ebola Antibody Order Payable in Cell Banks
In Boston biotech, “going to the bank” can mean a meeting with a lender or a trip down the hall wearing insulated gloves. This week I’ll take the second meeting. Somewhere in the journey from an idea for an antibody to a medicine somebody can actually receive, a team has to take delivery of living cells, put them away, and be reasonably confident it can get back to work when it opens the freezer. This week, Boston-based Asimov and Maryland-based Emergent BioSolutions announced two cell line development campaigns, one for each of two monoclonal antibodies targeting Ebola. Each campaign runs through shipment of a research cell bank. Emergent brings experience developing and manufacturing medical countermeasures. Asimov brings its CHO Edge system and the people who will do the work. The announcement gives no contract price, shipment date or clinical results. It does give us a deliverable, which puts it several lengths ahead of the average press release containing the word “partnership.” ## What exactly arrives in the box? An antibody is a protein. A monoclonal antibody candidate has a particular molecular identity, and researchers need a dependable supply of material with that identity to study it. Knowing which antibody you want leaves a fairly large purchasing question open. Who is going to make the stuff, and what will the next team start from when it needs more? A cell line is a population of cells that researchers can keep growing. Here, the cells are meant to produce the antibody. A research bank preserves portions of that population so that future work can begin from a common starting point. Think about the difference between handing a colleague a slice of sourdough and handing over some starter. Now imagine a workplace where somebody takes minutes at the starter handoff. For this application, I find myself firmly on the side of the minutes. The companies describe the intended banks as “high-titer.” In plain English, they want the cells to produce a relatively high concentration of antibody. Concentration matters because a research team needs actual material to examine, and a productive line makes that job easier. The partners give no numerical target or measured result for either candidate. Even an excellent concentration figure would answer a production question. Whether an antibody helps someone sick with Ebola is a different question, requiring its own evidence. ## The software has a shipping department Asimov calls its platform AI-native. I used to do predictive analytics, so my professional instinct is to ask what happens after the prediction. Here there is a satisfying answer. The company pairs its Kernel design software with a system built around Chinese hamster ovary cells, commonly shortened to CHO. The software contributes to design decisions. Living cells have to produce the material. At the far end of the agreement, somebody at Emergent should have something tangible to receive. That division of labor gives outsiders a decent way to judge the AI pitch. A screenshot can show that a design exists. A bank that another team can use has survived more encounters with reality, including the unusually rigorous peer review administered by a shipping address. We still don’t know how much time the software will save on these projects, how its choices will compare with other approaches, or what each campaign will cost. Those would be interesting results to report when there are results. ## Two candidates make for honest arithmetic There’s a modest virtue in the number two. It tells us the scale of the commitment and preserves a distinction that gets lost when the phrase “Ebola breakthrough” starts warming up in the headline bullpen. The partners have agreed to work on two candidates. They haven’t said the two will be administered together, established how either will perform in patients, or announced doses available for an emergency. A freezer full of research material and a public health stockpile occupy very different places on a calendar. For someone outside Massachusetts, that calendar is the reason to care. Preparedness involves paying attention to decisions whose value may only become obvious much later. If scientists want to compare candidates, they need enough material to make the comparison meaningful. If they decide to concentrate on one, the people doing the next round of work benefit from knowing where their starting material came from. An agreed handoff makes those future choices easier to imagine and, eventually, easier to make. ## A Boston export with the homework attached Asimov was founded by bioengineers from MIT and Boston University and is headquartered in Boston. The useful local detail is what those engineers have built a business around. A company elsewhere can buy a piece of development work with a defined endpoint. You can draw a straight line from university engineering talent to a customer’s receiving dock without detouring through a panel discussion about the innovation economy. Somewhere along the Red Line, a moderator has just gained forty minutes. This is familiar territory for a region where Azenta makes a business of keeping samples usable and Bluefin built software for the operational headaches of clinical trials. The drama tends to accrue farther downstream, when a developer like Cambridge’s Apnimed reaches FDA review. Much earlier, somebody has to produce an object another person can trust enough to spend the next research dollar on it. My verdict is a serious manufacturing bet, sensibly sized. Give the partners credit for saying where their work together is supposed to end. When a bank ships, the interesting follow-up will be what Emergent can learn with the material it receives. Until then, two concrete assignments and a place to send the results are quite enough news for one Tuesday. Boston can save the ballroom deposit.
www.siliconsnark.com
November 17, 2026 at 5:13 PM
We are not after your money here!, we just want a nomination so that our charity is in with a chance of winning a £1000 donation with the Movement for Good Awards.
Nominate us here:
movementforgood.com/draws/1000
Charity Name: NF2 BIOSOLUTIONS UK
Charity Number: 1189618
Repost
November 15, 2026 at 11:02 AM
We’re building toward a future where an NF2 diagnosis comes with a life-changing treatment option. Where children and adults keep their hearing, their balance and their independence. Where scan day becomes just another appointment.
Donation - NF2 BioSolutions UK
Donation - We are a registered UK charity that supports research to bring an end to the pain and suffering of children and adults with Neurofibromatosis Type 2 (NF2). NF2 is very rare with under 2000…
www.peoplesfundraising.com
November 17, 2026 at 5:08 PM
On December 1st, we’re coming together for Giving Tuesday to fuel our bold vision. Please save the date and plan to rally with us! Every like, share, donation, and conversation with a friend helps us bring a future beyond NF2 to life.

Give early: www.peoplesfundraising.com/donation/nf2...
Donation - NF2 BioSolutions UK
Donation - We are a registered UK charity that supports research to bring an end to the pain and suffering of children and adults with Neurofibromatosis Type 2 (NF2). NF2 is very rare with under 2000…
www.peoplesfundraising.com
November 17, 2026 at 5:08 PM
Catalera BioSolutions secures CAD 137,989 in non-dilutive funding from Natural Products Canada to advance biological seed-coating technology through Canadian field trials.

bipsiq.com/catalera-bio...
November 11, 2026 at 7:11 PM
🇺🇸x🇳🇱精密発酵ホエイタンパク質の生産拡大に向け、Strive NutritionとDyadic、BRIG BIOが提携

将来的な認可取得と製品化を見据えた3社間提携🤝を開始しました。

精密発酵技術を用いて、乳児向けや医療用の栄養食品に広く利用される「α-ラクトアルブミン」を生産。

2028年初頭に米国での販売に必要なGRAS自己認証プロセスを完了させた後、初期段階で10トン超の生産量を実現する計画です。
framtiden.earth/2026/11/15/s...
精密発酵ホエイタンパク質の生産拡大に向け、Strive NutritionとDyadic、BRIG BIOが提携 – Framtiden
アニマルフリーミルクの「FREEMILK」ブランドを展開する米国・カンザス州のStrive Nutritionと、フロリダ州のDyadic Applied BioSolutions、オランダの精密発酵企業BRIG BIOが3社間提携を開始しました。
framtiden.earth
November 17, 2026 at 7:03 AM
Dyadic Applied Biosolutions reports 3Q
*Reports very modest 1st protein product sales
*Milk collab with BRIG BIO & Strive
*Preclinical RSV & Malaria study with C1-produced mAb starts
*Call @ 5 pm ET
#$DYAI
dyadic.com/dyadic-annou...
Dyadic Announces Third Quarter 2026 Financial Results and Recent Developments - Dyadic
Advances Commercialization, Expands Strategic Partnerships and Accelerates Biopharmaceutical Platform Validation
dyadic.com
November 12, 2026 at 9:23 PM
Dyadic Applied Biosolutions signs collaboration with Brig Bio & Strive Nutrition
*To accelerate commercialization of α-lactalbumin in US
*10 metric tonne target going to 200
*May simplify the isolation of the protein for nutritional products
#$DYAI
finance.yahoo.com/healthcare/a...
Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets...
JUPITER, Fla., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Corp. today announced a s...
finance.yahoo.com
November 10, 2026 at 2:32 PM
Strive Nutrition Taps Dyadic & Brig Bio to Scale Up Animal-Free Whey Protein
US food tech startup Strive Nutrition has teamed up with Dyadic Applied BioSolutions and Brig Bio to scale up production and speed up commercialisation of its precision-fermented whey protein. Strive Nutrition, the company behind the Freemilk brand, is looking to boost the production and commercialisation of its recombinant whey protein through a new strategic collaboration. The Wichita-based startup has partnered with US biotech player Dyadic Applied BioSolutions and Dutch precision fermentation specialist Brig Bio to advance its cow-free alpha-lactalbumin protein. The deal combines Dyadic’s Dapibus protein production platform and expertise in strain optimisation and scale-up with Brig Bio’s precision fermentation commercialisation and regulatory capabilities and Strive’s Freemilk product development and go-to-market know-how. The three firms are aiming to advance the development of Strive’s precision-fermented whey protein and expand its market presence for use in next-gen nutrition products, including the latter’s own Freemilk range of animal-free milks. They’re targeting regulatory clearance for the ingredient in 2028. Strive expands from one cow-free whey protein to another Strive first launched Freemilk in 2022, using a recombinant beta-lactoglobulin protein from precision fermentation pioneer Perfect Day. Its current range includes this protein, but the company has been working with others on this animal-free dairy protein,...
www.greenqueen.com.hk
November 12, 2026 at 1:43 AM
#DYAI Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercia…

https://www.stocktitan.net/news/DYAI/dyadic-applied-bio-solutions-brig-bio-and-strive-nutrition-announce-8tmxp4f92t44.html?utm_source=stocktitan-bluesky&utm_medium=social
Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets in the U.S.
Dyadic International (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, announced a collaboration with BRIG BIO and Strive Nutrition to develop precision-fermented bovine alpha-lactalbumin.The protein is intended for potential use in Strive’s FREEMILK platform and other nutrition products. Dyadic and BRIG BIO will optimize production, while Strive will evaluate samples for formulation and application testing. The parties target initial commercial availability of more than 10 metric tonnes after completing the self-affirmed GRAS process for food-ingredient safety, currently targeted for early 2028. Their longer-term production target is more than 200 metric tonnes annually. Commercialization depends on successful development, scale-up, regulatory readiness, quality qualification and definitive commercial agreements. A commercial supply agreement remains to be negotiated after successful evaluation and satisfaction of regulatory and quality requirements.
www.stocktitan.net
November 10, 2026 at 12:30 PM
At LHSCRI, the London Urology BioSolutions Repository (LUBSR) supports researchers as they work to advance discoveries in urological research.

Go behind the scenes with Program Coordinator Kes Sebborn to learn more about the work happening in the urology biobank: www.lhscri.ca/news/buildin...
November 10, 2026 at 2:07 PM
🚨 $EBS (Emergent BioSolutions) · up to $22M · ≈ 7.3% of market value
Emergent BioSolutions Inc.: EX-99.1 2 a1142026biothraxmodpr htm EX-99.1 PR 11.4.2026 Document Emergent BioSolutions Receives 22.3 Million Delivery Order Modification to Supply
Source: SEC…
Live feed: https://t.me/UncleSamWire
November 4, 2026 at 9:07 PM
Dyadic Applied Biosolutions' President & Chief Operating Officer, Joe Hazelton, highlights how quickly the C1 and Dapibus platforms can move from DNA to a stable cell line.
#biotechnology #Biomanufacturing #LifeSciences #AlternativeProteins #PrecisionFermentation #$DYAI
youtube.com/shorts/BLDiJ...
From DNA To Stable Cell Line in 15 Days
YouTube video by Unboxing Biotech
youtube.com
November 5, 2026 at 12:37 AM
Upcoming event in Wageningen: Biobased Solutions Summit, happening May 11-13 2027. With international speakers discussing the development of biobased advanced materials. @w-u-r.bsky.social

From cellulose to mycelium, and lignin to LLPS… #glycotime and more!

www.biobased-solutions-summit.nl
Home | BioSolutions summit
www.biobased-solutions-summit.nl
November 4, 2026 at 11:33 AM
Trading Resumed for $EBS Emergent BioSolutions Inc. Common Stock | at 09:37:25 ET on NYSE | 2026-11-03
November 3, 2026 at 2:38 PM
🚨 $EBS
On November 4, 2026 , Emergent BioSolutions Inc. announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax ® (Anthrax Vaccine Adsorbed) to the U.S. Department of War. The first delivery, whic...
SEC Filing: EBS
Click to view the official SEC document.
www.sec.gov
November 4, 2026 at 9:15 PM